Further studies have also highlighted a high tumor heterogeneity between metastatic lesions and primary tumors in the same NSCLC patients in terms of both pathway activation and PD-L1 expression [73], which may impact chemotherapy and immunotherapy response. This evidence concerns the gene CD274 and non-small cell lung carcinoma.